Advanced Cancer Clinical Trial
Official title:
Randomized Study of a Hospice Video Educational Tool for Patients With Advanced Cancer and Their Caregivers
NCT number | NCT03040102 |
Other study ID # | 17-026 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 9, 2017 |
Est. completion date | February 1, 2019 |
Verified date | August 2022 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to compare two ways to educate patients with cancer and their caregivers about hospice care services
Status | Completed |
Enrollment | 194 |
Est. completion date | February 1, 2019 |
Est. primary completion date | February 1, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients Eligibility Criteria: - Adult patients (=18 years) with a diagnosis of metastatic solid cancer. - A prognosis of 12 months or less based on the treating oncologist's assessment. - The ability to provide informed consent. - Ability to comprehend and speak English. Caregivers Eligibility Criteria: - Adult caregivers (>18 years) of patients who have agreed to participate in study. - A relative or a friend upon whom the patient relies for help and who will be likely to be present during hospitalization, or willing to participate by phone. - Ability to comprehend and speak English. Exclusion Criteria: Patients Exclusion Criteria: -Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts general Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | Gordon and Betty Moore Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient Perception of Hospice Care Questionnaire | we will assess perception of hospice using the Hospice Perception Questionnaire | immediately after the video intervention or verbal narrative | |
Other | Patient Hospice Utilization | We will assess patient hospice utilization and length of stay in hospice | 1 year after study completion | |
Other | Caregiver Preference for Hospice Question | we will assess caregiver's preference for their loved one using hospice (yes vs. no) | immediately after the video intervention or verbal narrative | |
Other | Caregiver Knowledge about Hospice Questionnaire | we will assess knowledge about hospice using 10 knowledge questions | immediately after the video intervention or verbal narrative | |
Other | Caregiver Perception of Hospice Care Questionnaire | we will assess perception of hospice using the Hospice Perception Questionnaire | immediately after the video intervention or verbal narrative | |
Other | Caregiver satisfaction with end-of-life care (FAMCARE) | We will use 9 items from the FAMCARE to assess caregivers' satisfaction with patient's end of life care | 1 year after study completion | |
Primary | Patient Preference for Hospice Question | We will ask patients whether they would prefer to receive hospice care at the end of life (yes vs. no) | immediately after the video intervention or verbal narrative | |
Secondary | Patient knowledge about hospice Questionnaire | we will assess knowledge about hospice using 10 knowledge questions | immediately after the video intervention or verbal narrative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |